The Chemours Company (NYSE:CC) Shares Purchased by Trexquant Investment LP

Trexquant Investment LP lifted its stake in The Chemours Company (NYSE:CC - Free Report) by 192.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 114,598 shares of the specialty chemicals company's stock after purchasing an additional 75,372 shares during the period. Trexquant Investment LP owned approximately 0.08% of Chemours worth $1,937,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in shares of Chemours by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 15,223,961 shares of the specialty chemicals company's stock valued at $257,285,000 after purchasing an additional 94,885 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Chemours by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 2,491,748 shares of the specialty chemicals company's stock valued at $50,646,000 after buying an additional 28,803 shares during the period. Norges Bank acquired a new stake in Chemours during the fourth quarter worth about $30,702,000. American Century Companies Inc. increased its position in Chemours by 7.6% during the 4th quarter. American Century Companies Inc. now owns 1,625,019 shares of the specialty chemicals company's stock worth $27,463,000 after purchasing an additional 115,436 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Chemours by 6.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,302,272 shares of the specialty chemicals company's stock valued at $22,008,000 after acquiring an additional 73,220 shares during the period. Hedge funds and other institutional investors own 76.26% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several equities research analysts recently commented on CC shares. Truist Financial dropped their target price on Chemours from $27.00 to $22.00 and set a "buy" rating on the stock in a report on Monday. BMO Capital Markets dropped their price objective on shares of Chemours from $34.00 to $27.00 and set an "outperform" rating on the stock in a research note on Wednesday, February 19th. Morgan Stanley lowered their price target on shares of Chemours from $25.00 to $22.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Barclays cut their price objective on shares of Chemours from $19.00 to $16.00 and set an "equal weight" rating on the stock in a report on Tuesday, April 1st. Finally, Mizuho upgraded Chemours from a "neutral" rating to an "outperform" rating and set a $19.00 target price for the company in a research note on Thursday, March 27th. Four research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Chemours currently has an average rating of "Moderate Buy" and a consensus target price of $22.00.

Chemours Stock Performance

NYSE:CC traded up $0.24 during trading hours on Monday, reaching $11.52. 138,557 shares of the stock were exchanged, compared to its average volume of 1,815,207. The Chemours Company has a 52 week low of $9.33 and a 52 week high of $29.21. The company has a quick ratio of 0.92, a current ratio of 1.68 and a debt-to-equity ratio of 6.70. The stock has a market capitalization of $1.72 billion, a P/E ratio of 20.21 and a beta of 1.84. The firm has a 50 day simple moving average of $14.54 and a 200-day simple moving average of $17.60.

Chemours (NYSE:CC - Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The specialty chemicals company reported $0.11 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $0.01. The firm had revenue of $1.36 billion during the quarter, compared to the consensus estimate of $1.37 billion. Chemours had a net margin of 1.51% and a return on equity of 26.54%. As a group, sell-side analysts forecast that The Chemours Company will post 2.03 earnings per share for the current fiscal year.

Chemours Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 14th. Investors of record on Friday, February 28th were paid a dividend of $0.25 per share. The ex-dividend date was Friday, February 28th. This represents a $1.00 annualized dividend and a yield of 8.68%. Chemours's dividend payout ratio (DPR) is 175.44%.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.